154 related articles for article (PubMed ID: 179316)
1. The clinical usefulness of narcotic antagonists: implications of behavioral research.
Meyer RE; Mirin SM; Altman JL
Am J Drug Alcohol Abuse; 1975; 2(3-4):417-32. PubMed ID: 179316
[No Abstract] [Full Text] [Related]
2. Methadone maintenance and narcotic blocking drugs.
Wikler A
Int J Addict; 1977 Oct; 12(7):851-6. PubMed ID: 201577
[TBL] [Abstract][Full Text] [Related]
3. Analysis and modification of opiate reinforcement.
Meyer RE; McNamee HB; Mirin SM; Altman JL
Int J Addict; 1976; 11(3):467-84. PubMed ID: 184053
[TBL] [Abstract][Full Text] [Related]
4. Methadone maintenance and narcotic blocking drugs. Appendix.
Wikler A
Int J Addict; 1977 Oct; 12(7):869-81. PubMed ID: 338517
[TBL] [Abstract][Full Text] [Related]
5. Opiate antagonists and the modification of heroin self-administration behavior in man: an experimental study.
Altman JL; Meyer RE; Mirin SM; McNamee HB
Int J Addict; 1976; 11(3):485-99. PubMed ID: 184054
[TBL] [Abstract][Full Text] [Related]
6. A behavioral paradigm for the evaluation of narcotic antagonists.
Meyer RE; Mirin SM; Altman JL; McNamee HB
Arch Gen Psychiatry; 1976 Mar; 33(3):371-7. PubMed ID: 944026
[TBL] [Abstract][Full Text] [Related]
7. Limitations of an extinction approach to narcotic antagonist treatment.
Meyer R; Randall R; Barrington C; Mirin S; Greenberg I
NIDA Res Monogr; 1976 Sep; (9):123-35. PubMed ID: 187940
[No Abstract] [Full Text] [Related]
8. Narcotic antagonists in the treatment of opioid dependence: review and commentary.
Resnick RB; Schuyten-Resnick E; Washton AM
Compr Psychiatry; 1979; 20(2):116-25. PubMed ID: 421447
[No Abstract] [Full Text] [Related]
9. NIDA's naltrexone research program.
Julius D
NIDA Res Monogr; 1976 Sep; (9):5-11. PubMed ID: 187943
[No Abstract] [Full Text] [Related]
10. Blockade with methadone, cyclazocine, and naloxone.
Freedman AM; Zaks A; Resnick R; Fink M
Int J Addict; 1970 Sep; 5(3):507-15. PubMed ID: 5524385
[No Abstract] [Full Text] [Related]
11. Narcotic antagonists: naltrexone progress report: foreword.
Jaffe J
NIDA Res Monogr; 1976 Sep; (9):v-vii. PubMed ID: 1088898
[No Abstract] [Full Text] [Related]
12. Clinical experience with naltrexone.
O'Brien CP; Greenstein RA; Mintz J; Woody GE
Am J Drug Alcohol Abuse; 1975; 2(3-4):365-77. PubMed ID: 1227298
[No Abstract] [Full Text] [Related]
13. [Management of opium addicts using opiates and their antagonists].
Burchard JM
Nervenarzt; 1972 Oct; 43(10):501-4. PubMed ID: 4564819
[No Abstract] [Full Text] [Related]
14. Aftercare on narcotic antagonists: prospects and problems.
Rawlins M; Randall M
Int J Addict; 1976; 11(3):501-11. PubMed ID: 184055
[TBL] [Abstract][Full Text] [Related]
15. Strategies for preventing heroin overdose.
Sporer KA
BMJ; 2003 Feb; 326(7386):442-4. PubMed ID: 12595388
[No Abstract] [Full Text] [Related]
16. Naltrexone in methadone maintenance patients electing to become "drug free".
Haas N; Ling W; Holmes E; Blakis M; Litaker M
NIDA Res Monogr; 1976 Sep; (9):70-3. PubMed ID: 794723
[No Abstract] [Full Text] [Related]
17. Naltrexone: the clinical investigator's dilemma.
Ling W
NIDA Res Monogr; 1978; (19):308-14. PubMed ID: 106297
[No Abstract] [Full Text] [Related]
18. Predictors of retention in naltrexone maintenance for opioid dependence: analysis of a stage I trial.
Sullivan MA; Rothenberg JL; Vosburg SK; Church SH; Feldman SJ; Epstein EM; Kleber HD; Nunes EV
Am J Addict; 2006; 15(2):150-9. PubMed ID: 16595353
[TBL] [Abstract][Full Text] [Related]
19. Regarding naltrexone for probationers and parolees.
Stancliff S
J Subst Abuse Treat; 2007 Mar; 32(2):217-8; author reply 218-9. PubMed ID: 17306730
[No Abstract] [Full Text] [Related]
20. Evolution of the National Academy of Sciences study of naltrexone.
Kaim SC
NIDA Res Monogr; 1976 Sep; (9):37-44. PubMed ID: 794719
[No Abstract] [Full Text] [Related]
[Next] [New Search]
